Hemodialysis patients make long-lived antibodies against SARSCOV-2 that may be associated with reduced reinfection

Gemma Banham; Alexandra Godlee; Sian Faustini; Adam Cunningham; Alex Richter; Lorraine Harper; Claire Backhouse; Anna Casey; Lynsey Dunbar; Beena Emmanuel; Megan Fahy; Paul Moss; Peter Nightingale; Liz Ratcliffe; Stephanie  Stringer

doi:10.1681/ASN.2021020188

Hemodialysis patients make long-lived antibodies against SARSCOV-2 that may be associated with reduced reinfection

Gemma Banham, Alexandra Godlee, Sian Faustini, Adam Cunningham, Alex Richter, Lorraine Harper, Claire Backhouse (Contributor), Anna Casey (Contributor), Lynsey Dunbar (Contributor), Beena Emmanuel (Contributor), Megan Fahy (Contributor), Paul Moss (Contributor), Peter Nightingale (Contributor), Liz Ratcliffe (Contributor), Stephanie Stringer (Contributor)

Research output: Contribution to journal › Letter › peer-review

261 Downloads (Pure)

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections have a devastating effect on patients receiving hemodialysis. To what extent infection-induced antibody responses are maintained, or protective, is unknown. This study describes the evolution of antibodies against the SARS-CoV-2 spike protein in a cohort of 990 patients on hemodialysis. During the first wave of the pandemic, 26% of patients had developed antispike SARS-CoV-2 antibodies. Fewer PCR-confirmed second-wave infections were observed in patients with pre-existing antibodies (4.2%) than those without antibodies (11.4%). This study shows that SARS-CoV-2 antibodies in patients on hemodialysis are well maintained and associate with reduced risk of subsequent SARS-CoV-2 infection.

Original language	English
Pages (from-to)	2140-2142
Number of pages	3
Journal	Journal of the American Society of Nephrology
Volume	32
Issue number	9
Early online date	2 Aug 2021
DOIs	https://doi.org/10.1681/ASN.2021020188
Publication status	Published - Sept 2021

Keywords

Antibody
COVID-19
Haemodialysis
SARS-CoV-2

Access to Document

10.1681/ASN.2021020188

BanhamG2021Hemodialysis
Banham, G.D. et al., 2021. Hemodialysis Patients Make Long-Lived Antibodies against SARS-CoV-2 that May Be Associated with Reduced Reinfection. Journal of the American Society of Nephrology, 32(9), pp.2140–2142. Available at: http://dx.doi.org/10.1681/asn.2021020188.
Accepted author manuscript, 260 KBLicence: None: All rights reserved

Cite this

Banham, G., Godlee, A., Faustini, S., Cunningham, A., Richter, A., Harper, L., Backhouse, C., Casey, A., Dunbar, L., Emmanuel, B., Fahy, M., Moss, P., Nightingale, P., Ratcliffe, L., & Stringer, S. (2021). Hemodialysis patients make long-lived antibodies against SARSCOV-2 that may be associated with reduced reinfection. Journal of the American Society of Nephrology, 32(9), 2140-2142. https://doi.org/10.1681/ASN.2021020188

@article{7871873896dc443d84b85ee4a073a67d,

title = "Hemodialysis patients make long-lived antibodies against SARSCOV-2 that may be associated with reduced reinfection",

abstract = "Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections have a devastating effect on patients receiving hemodialysis. To what extent infection-induced antibody responses are maintained, or protective, is unknown. This study describes the evolution of antibodies against the SARS-CoV-2 spike protein in a cohort of 990 patients on hemodialysis. During the first wave of the pandemic, 26\% of patients had developed antispike SARS-CoV-2 antibodies. Fewer PCR-confirmed second-wave infections were observed in patients with pre-existing antibodies (4.2\%) than those without antibodies (11.4\%). This study shows that SARS-CoV-2 antibodies in patients on hemodialysis are well maintained and associate with reduced risk of subsequent SARS-CoV-2 infection.",

keywords = "Antibody, COVID-19, Haemodialysis, SARS-CoV-2",

author = "Gemma Banham and Alexandra Godlee and Sian Faustini and Adam Cunningham and Alex Richter and Lorraine Harper and Claire Backhouse and Anna Casey and Lynsey Dunbar and Beena Emmanuel and Megan Fahy and Paul Moss and Peter Nightingale and Liz Ratcliffe and Stephanie Stringer",

year = "2021",

month = sep,

doi = "10.1681/ASN.2021020188",

language = "English",

volume = "32",

pages = "2140--2142",

journal = "Journal of the American Society of Nephrology",

issn = "1046-6673",

publisher = "American Society of Nephrology",

number = "9",

}

Banham, G, Godlee, A, Faustini, S , Cunningham, A , Richter, A , Harper, L, Backhouse, C, Casey, A, Dunbar, L, Emmanuel, B, Fahy, M, Moss, P, Nightingale, P, Ratcliffe, L & Stringer, S 2021, 'Hemodialysis patients make long-lived antibodies against SARSCOV-2 that may be associated with reduced reinfection', Journal of the American Society of Nephrology, vol. 32, no. 9, pp. 2140-2142. https://doi.org/10.1681/ASN.2021020188

TY - JOUR

T1 - Hemodialysis patients make long-lived antibodies against SARSCOV-2 that may be associated with reduced reinfection

AU - Banham, Gemma

AU - Godlee, Alexandra

AU - Faustini, Sian

AU - Cunningham, Adam

AU - Richter, Alex

AU - Harper, Lorraine

A2 - Backhouse, Claire

A2 - Casey, Anna

A2 - Dunbar, Lynsey

A2 - Emmanuel, Beena

A2 - Fahy, Megan

A2 - Moss, Paul

A2 - Nightingale, Peter

A2 - Ratcliffe, Liz

A2 - Stringer, Stephanie

PY - 2021/9

Y1 - 2021/9

N2 - Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections have a devastating effect on patients receiving hemodialysis. To what extent infection-induced antibody responses are maintained, or protective, is unknown. This study describes the evolution of antibodies against the SARS-CoV-2 spike protein in a cohort of 990 patients on hemodialysis. During the first wave of the pandemic, 26% of patients had developed antispike SARS-CoV-2 antibodies. Fewer PCR-confirmed second-wave infections were observed in patients with pre-existing antibodies (4.2%) than those without antibodies (11.4%). This study shows that SARS-CoV-2 antibodies in patients on hemodialysis are well maintained and associate with reduced risk of subsequent SARS-CoV-2 infection.

AB - Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections have a devastating effect on patients receiving hemodialysis. To what extent infection-induced antibody responses are maintained, or protective, is unknown. This study describes the evolution of antibodies against the SARS-CoV-2 spike protein in a cohort of 990 patients on hemodialysis. During the first wave of the pandemic, 26% of patients had developed antispike SARS-CoV-2 antibodies. Fewer PCR-confirmed second-wave infections were observed in patients with pre-existing antibodies (4.2%) than those without antibodies (11.4%). This study shows that SARS-CoV-2 antibodies in patients on hemodialysis are well maintained and associate with reduced risk of subsequent SARS-CoV-2 infection.

KW - Antibody

KW - COVID-19

KW - Haemodialysis

KW - SARS-CoV-2

UR - https://www.scopus.com/pages/publications/85114188895

U2 - 10.1681/ASN.2021020188

DO - 10.1681/ASN.2021020188

M3 - Letter

SN - 1046-6673

VL - 32

SP - 2140

EP - 2142

JO - Journal of the American Society of Nephrology

JF - Journal of the American Society of Nephrology

IS - 9

ER -

Hemodialysis patients make long-lived antibodies against SARSCOV-2 that may be associated with reduced reinfection

Abstract

Keywords

Access to Document

Fingerprint

Cite this